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Highlights 
 Expectancies and self-efficacy are key cognitive constructs in cannabis dependence 
 First study to measure both constructs as treatment outcome predictors 
 Emotional relief refusal self-efficacy was robust predictor of treatment outcome 
 Negative cannabis expectancy predicted lower likelihood of lapse 
 Self-efficacy may mediate risk conveyed by positive cannabis expectancy 
 
ABSTRACT 
Background: Drug-related outcomes expectancies and refusal self-efficacy are core 
components of Social Cognitive Theory. Both predict treatment outcome in alcohol use 
disorders. Few studies have reported expectancies and refusal self-efficacy in cannabis 
dependence. None have examined both, although both constructs are key targets in 
Cognitive-Behavioural Therapy (CBT). This study tests the predictive role of expectancies 
and refusal self-efficacy in treatment outcome for cannabis dependence. Design: Outpatients 
completed a comprehensive assessment when commencing cannabis treatment and predictors 
of treatment outcome were tested. Setting: A university hospital alcohol and drug outpatient 
clinic. Participants: 221 cannabis-dependent patients participated in a 6-week CBT program 
where the goal was abstinence. Measurements: Cannabis Expectancy Questionnaire and 
Cannabis Refusal Self-Efficacy Questionnaire, cannabis dependence severity [Severity of 
Dependence Scale], psychological distress [General Health Questionnaire] at baseline; the 
timeline follow-back procedure at baseline and each session. Findings: Patients reporting 
lower confidence in their ability to resist cannabis during high negative affect (emotional 
relief refusal self-efficacy) had a lower likelihood of abstinence (p = .004), more days of use 
(p < .001), and larger amount used (p < .001). Negative cannabis expectancies predicted 
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greater likelihood of abstinence (p = .024). Higher positive expectancies were associated with 
lower emotional relief self-efficacy, mediating its association with outcome (p < .001). 
Conclusions: Emotional relief refusal self-efficacy and negative expectancies are predictive 
of better treatment outcomes for cannabis dependence. Positive expectancies may indirectly 
predict poorer outcome because of a negative association with self-efficacy, but this 
conclusion remains tentative as directionality could not be established. 
Keywords: cannabis dependence, expectancies, self-efficacy, treatment, CBT 
1. INTRODUCTION 
Cannabis is the most widely used illicit drug with 2.8 to 4.5% of the adult global 
population estimated as cannabis users (Degenhardt and Hall, 2012). In the most recent 
Australian survey, lifetime prevalence of cannabis dependence is approximately 3% when 
using criteria from the fourth edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV; Mewton et al., , 2013). Compared to the fifth edition, DSM-IV cannabis 
dependence is equivalent to moderate-to-severe cannabis use disorder (4+ criteria met; 
American Psychiatric Association, 2013). Cannabis dependence is associated with a wide 
variety of adverse physical and mental health consequences (Hall and Degenhardt, 2009; Hall 
and Pacula, 2003). No medications have been approved for the treatment of cannabis 
dependence (Justinova et al., 2013). Psychological therapies are the first line of treatment 
(Davis et al., 2015; Litt et al., 2008). Cognitive-behavioural therapy (CBT) is among the most 
effective (Babor and The Marijuana Treatment Project Research Group, 2004; Budney et al., 
2006; Carroll et al., 2006; Hoch et al., 2014). Relapse rates remain high. Determining 
predictors of outcome is required to inform more effective treatment (McRae et al., 2003; 
Moore and Budney, 2003). 
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Social Cognitive Theory (SCT) emphasizes the importance of two domains of 
cognition in bringing about behaviour change, both of which can be affected by vicarious 
experience or modeling (Bandura, 1986). Outcome expectancies describe an individual’s 
belief that a particular behaviour will produce certain outcomes (Bandura, 1977, 2001; Jones 
et al., 2001). According to SCT, expectancies about the effects of substance use play an 
important role in consumption, dependence, and treatment. Evidence links expectancies to all 
of these outcomes (Boden et al., 2013; Connor et al., 2007; Jones et al., 2001; Young et al., 
2011). Expectancies have been shown to predict cannabis use and dependence (Connor et al., 
2014). Positive cannabis expectancies are predicted to increase motivation to consume 
cannabis, and negative expectancies to decrease it (Connor et al., 2011). 
 Self-efficacy forms the second key component of SCT. Refusal (or abstinence) self-
efficacy has received most research attention. This is belief in the ability to refuse an abused 
substance. Low refusal self-efficacy is hypothesised to undermine motivation for abstinence 
and predict poorer outcomes (Bandura, 1999; Oei and Baldwin, 1994). In their review, 
Kadden and Litt (2011) reported low refusal self-efficacy consistently predicted poorer post-
treatment outcomes across substances. Self-efficacy for avoiding cannabis after completing 
treatment predicted cannabis use at 12 months over-and-above past consumption, peer use, 
temptation, and stress (Stephens et al., 1995). In a comparison of different psychological 
treatments for cannabis dependence, Litt and colleagues (2008) reported increases in refusal 
self-efficacy to be a primary common mechanism through which 12-month outcomes were 
achieved.  
Most previous studies have employed ad hoc global measures of refusal or abstinence 
self-efficacy. Young et al.  (2012) developed the Cannabis Refusal Self-Efficacy 
Questionnaire (CRSEQ), a theoretically-driven and psychometrically robust assessment of 
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self-efficacy. The measure assesses situational confidence to refuse cannabis consumption for 
emotional relief, social facilitation, and opportunistically. These subtypes of refusal self-
efficacy may be differentially related to clinical outcomes. In a large sample of court-referred 
cannabis users, Young et al. reported all three subtypes were associated with lower 
consumption, but only high emotional relief self-efficacy was related to lower severity of 
cannabis dependence.  
Despite evidence that both cognitive domains individually predict substance use 
outcomes (Boden et al., 2013; Connor et al., 2007; Jones et al., 2001; Kadden and Litt, 2011; 
Young et al., 2011), refusal self-efficacy and outcome expectancies have rarely been 
examined together, particularly in clinical populations. According to SCT, refusal self-
efficacy should mediate the relationship between expectancies and treatment outcomes 
(Bandura, 1999; Oei and Baldwin, 1994). Those holding more positive (or less negative) 
beliefs about using cannabis should find it more difficult to refuse it in cued situations. Low 
refusal self-efficacy has been found to mediate the association between positive alcohol 
expectancies and problematic drinking in patients undergoing treatment, college students, and 
adolescents (Connor et al., 2011; Gullo et al., 2010). Given the significant correlation 
between the two, not including both expectancies and self-efficacy in predictive models could 
have obscured previous findings and the identification of priority targets for CBT (Connor et 
al., 2014).  
Connor and colleagues (2014) investigated the combined role of expectancies and 
refusal self-efficacy in 1,115 cannabis users referred for assessment by the courts as an 
alternative to prosecution. In this cross-sectional study, refusal self-efficacy fully mediated 
the relationship between negative cannabis expectancies and weekly consumption. It partially 
mediated the effects of positive expectancies on weekly consumption. Expectancies and 
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refusal self-efficacy are also likely to be associated with treatment outcome. To date, no study 
has investigated the influence of both expectancies and refusal self-efficacy as predictors of 
treatment outcome in cannabis dependence. 
The current study investigated the relationship between outcome expectancies, refusal 
self-efficacy and treatment outcome among cannabis-dependent outpatients. Outcomes of 
interest were cannabis abstinence, number of days of use, and amount used. The secondary 
aim of the study was to test the hypothesised mediational relationship between these 
constructs as outlined in SCT. According to SCT, refusal self-efficacy should mediate the 
relationship between expectancies and treatment outcomes. It was predicted that greater 
positive cannabis expectancies would be associated with lower refusal self-efficacy and, in 
turn, predict poorer treatment outcomes; fully mediating the relationship between 
expectancies and outcomes. A similar relationship was hypothesised for negative 
expectancies, refusal self-efficacy and treatment outcomes, but with lower negative 
expectancies being associated with lower self-efficacy and greater use.  
2. METHOD 
2.1. Participants and procedures 
Data were obtained from 221 treatment-seeking cannabis users who presented to an 
outpatient alcohol and drug clinic at an Australian metropolitan public hospital. All patients 
attended treatment voluntarily. An initial intake assessment was conducted by a clinical nurse 
or social worker prior to referral to a cognitive-behavioural cannabis treatment program 
where the goal was abstinence. The program comprised five 1-hr sessions delivered over six 
weeks, with the final session taking place one fortnight after session four. The program was 
delivered one-on-one by Masters- or Doctoral-qualified clinical psychologists. It included 
CBT and elements of motivational enhancement; specifically, craving management, cognitive 
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restructuring, relapse prevention, and motivational interviewing. Patients were not excluded 
from program if they lapsed, so long as they maintained abstinence as their goal. 
Questionnaires assessing refusal self-efficacy, cannabis expectancies, severity of dependence 
and psychosocial functioning were completed at the first treatment session. Dependence 
severity and psychosocial functioning could impact treatment response and were included as 
potential covariates (Stephens et al., 1993; White et al., 2004). Abstinence, numbers of days 
used, and amount of cannabis used were recorded at each session. Therapists were not aware 
of study aims. Hospital and university human research ethics approval was obtained.  
2.2. Measures 
2.2.1 Cannabis Expectancy Questionnaire (CEQ; Connor et al., 2011). The 45-item CEQ 
assessed positive (18 items, e.g., ‘Smoking cannabis makes me feel outgoing and friendly’) 
and negative outcome expectancies (27 items, e.g., ‘Smoking cannabis makes me confused’). 
Responses were rated on a 5-point Likert scale (1 = Strongly disagree to 5 = Strongly agree). 
Both subscales have excellent internal reliability (α = 0.89 and 0.93 for negative and positive 
expectancies, respectively (Connor, Gullo, et al., 2011). The factor structure and criterion 
validity of the CEQ has been confirmed across two samples (Connor et al., 2011).  
2.2.2. Cannabis Refusal Self-Efficacy Questionnaire (CRSEQ; Young et al., 2012). The 14-
item CRSEQ measured levels of cannabis refusal self-efficacy. Responses were rated on a 6-
point Likert scale (1 = I am very sure I could NOT resist smoking to 6 = I am very sure I 
could resist smoking. It comprises three subscales: Emotional relief (six items, e.g., ‘When I 
feel sad’), Opportunistic (five items, e.g., ‘When I am at a party’), and Social facilitation 
(three items, e.g., ‘When I want to feel more accepted by friends’). The measure has good-to-
excellent internal consistency (α = 0.97, 0.91 and 0.84 for each subscale, respectively) and its 
factor structure and criterion validity has been previously established (Young et al., 2012). 
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2.2.3. Severity of Dependence Scale–Cannabis (SDS-C; Swift et al.,, 1998). This five-item 
scale assesses degree of cannabis dependence experienced by users (e.g., Have you ever 
thought your cannabis use is out of control?). Responses are rated on a 4-point Likert scale (0 
= Never to 3 = Always). The SDS-C has good test-retest reliability and is sensitive to severity 
of cannabis dependence (Swift et al., 2000). Using Australian normative data, a score of ≥3 is 
indicative of DSM-IV cannabis dependence (Swift et al., 1998). 
2.2.4. Cannabis consumption. The Timeline Followback (Sobell and Sobell, 1992) was used 
to measure session-by-session cannabis consumption and abstinence status. This 
retrospective, calendar-based assessment is one of the most psychometrically robust measures 
of daily substance use (Robinson et al., 2014). Outcomes of interest were abstinence status (0 
= not abstinent, 1 = abstinent), number of days used, and total amount used (in grams).  
2.2.5. Psychological distress. The Anxiety, Depression, and Somatic Symptoms scales of the 
General Health Questionnaire-28 (GHQ-28) were used to assess psychological distress 
(Goldberg and Williams, 1988). Items assess recent changes in perceived health and 
wellbeing (e.g., Felt that life is not worth living) and rated on a 4-point Likert-type scale (0 = 
Not at all to 3 = Much more than usual). It has strong psychometric properties (Goldberg et 
al., 1997; Goldberg and Williams, 1988; Werneke et al., 2000). Higher scores reflect poorer 
functioning. 
2.3. Data analysis 
 Multi-level modelling (MLM) in MLwiN (version 2.30) was used to analyse the 
influence of expectancies and self-efficacy on treatment outcomes. MLM is particularly 
suited to analysing longitudinal clustered data; in this instance, sessions nested within 
patients (Hox, 2002). This is superior to analysing endpoint summary statistics, such as 
percentage days abstinent, as it allows for modelling of individual trajectories of change over 
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time. MLM is also suited to naturalistic settings where the number and frequency of sessions 
may vary across individuals. MLM utilises full information maximum likelihood (FIML) 
estimation, which are optimal for handling missing data (Graham, 2009), which is substantial 
in treatment studies. FIML produces less biased estimates than other missing data 
approaches, such as assuming relapse or carrying forward the last observation (Hallgren and 
Witkiewitz, 2013). Full iterative generalized least squares (IGLS) estimation, a type of FIML, 
was employed for days used and amount used models. Abstinence was analysed with 
generalized linear models utilising a logit link function and Taylor series expansion. In these 
models, coefficients represent logit transformed probabilities. To calculate effect size, they 
were converted to odds by finding the natural antilog (ex). Assumptions of linearity and 
normality were assessed by examination of residuals. Baseline models included a random 
intercept (constant, β0j), session number, and controlled for time (days) between sessions. 
Potential covariates were included (β3 - β10), but only retained if statistically significant: 
Abstinence/Days Used/Amount Usedij = β0j + β1 Time (days) between sessionsij + β2 
Session numberj + β3 High school completion:Yesj + β4 Severity of cannabis 
dependencej + β5Gender:Malej + β6 Agej + β7 Employment:Yesj + β8 Somatic 
Symptomsj + β9 Anxietyj + β10 Depressionj + eij. 
SCT predictors were added to the model on Step 2 (grand mean-centered), followed by SCT 
x session number interactions to investigate time-dependent effects. Predictors were tested for 
significance using the Wald test. Mediation was tested using the joint significance procedure, 
which is less prone to Type II error (MacKinnon et al., 2002) than the commonly-used 
‘causal steps’ procedure (Baron and Kenny, 1986). There is support for mediation where 
there is a significant association between IV and mediator (path a) and a significant 
association between mediator and DV (path b). The primary MLM analyses test path b of 
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mediation. Because IV and mediator were measured once, standard multiple regression was 
implemented to test path a (expectancies→self-efficacy). Mediation effects were estimated 
with the product-of-coefficients method using the PRODCLIN software to calculate 95% 
confidence intervals (MacKinnon et al., 2007). When estimating mediation effects for the 
abstinence outcome variable (dichotomous), a and b path coefficients were first standardized 
using procedures outlined in MacKinnon and Dwyer (1993) to correct for differences in 
mediator/outcome distributions and variance of the residual.  
3. RESULTS 
3.1. Descriptive statistics and missing data 
Nearly the entire sample was cannabis dependent (98.5%), with only three 
participants scoring below the ≥3 cut-off on SDS-C (Swift et al., 1998). The average number 
of sessions attended was three out of the total five, with 99 (44.8%) patients completing the 
treatment program. Of those, 66 (66.7%) had been abstinent for at least the past two weeks. 
Multi-level models are well equipped to account for missing values under most missing data 
conditions, especially for longitudinal designs (Graham, 2009; Tasca and Gallop, 2009), and 
Little’s (1988) Missing Completely At Random (MCAR) test on baseline data was not 
significant, χ2 (734) = 792.598, p = .066. Grand mean probability of abstinence was .68, 
95%CIs [.608, .748]. Grand mean amount of cannabis consumed between sessions was 1.31 
grams (SD = 4.09) and participants used the drug on 1.22 days between sessions (SD = 3.33). 
Sample descriptive statistics are reported in Table 1.  
3.2. Abstinence 
 In the baseline model, no covariate was statistically significant and were omitted. 
Session number predicted abstinence, with probability of abstinence increasing over the 
course of treatment. Patients were 1.20 times more likely to be abstinent with each session, 
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95%CIs [1.003, 1.43]. When SCT variables were added to the model, higher negative 
expectancies at baseline predicted greater abstinence. A +1 SD increase in negative 
expectancies increased the odds of abstinence by 40.4%. Emotional relief refusal self-
efficacy was also significant, with a +1 SD increase in self-efficacy associated with an 
increase in the odds of abstinence by 80%. SCT x session number interactions added on Step 
3 were not significant (ps > .05) and not retained. Therefore, the slope of increase in 
abstinence over the course of treatment was not moderated by baseline expectancies or self-
efficacy. The final model is summarised in Table 2.  
3.3. Number of days cannabis used  
 In the baseline model, no covariate was statistically significant. Session number was 
significant, with patients reporting fewer days of cannabis use as treatment progressed. 
Significant effects of SCT variables were found. Emotional relief self-efficacy predicted 
fewer days of cannabis use during treatment (Table 3). SCT x session number interactions 
added on Step 3 were not significant and not retained (ps > .05). The final model is 
summarised in Table 3.  
3.4. Amount of cannabis consumed 
 In the baseline model, no covariate was statistically significant. Session number was 
significant, with patients consuming, on average, 0.13 grams less cannabis per session. 
Significant effects of SCT variables were found. Emotional relief self-efficacy predicted a 
lower amount of cannabis use during treatment (Table 4). SCT x session number interactions 
added on Step 3 were not significant and not retained (ps > .05). The final model is 
summarised in Table 4. 
12 
3.5. Mediating role of refusal self-efficacy 
Emotional relief refusal self-efficacy was the only domain of self-efficacy predictive 
of cannabis use during treatment. To investigate its role as a potential mediator of expectancy 
effects, a standard multiple regression was conducted. Overall, 11% of the variance in 
emotional relief refusal self-efficacy was accounted for by expectancies (path α), F (2,207) = 
12.95, p < .001. Positive expectancies (β = -.33, p < .001) uniquely accounted for 10.5% of 
variance, but negative expectancies (β = -.12, p = .072) did not reach significance. Because 
positive expectancies were directly associated with emotional relief refusal self-efficacy (path 
a) and refusal self-efficacy predicted treatment outcome (path b), there was evidence for 
mediation according to the joint significance procedure. Furthermore, all mediation effects 
involving positive expectancies (predictor) and emotional relief refusal self-efficacy 
(mediator) estimated using the product-of-coefficients method were statistically significant 
(see Figure 1).  
4.  DISCUSSION 
This is the first study to test the unique role of cannabis outcome expectancies and 
refusal self-efficacy in treatment outcome. Results show emotional relief refusal self-efficacy 
was a consistent predictor of improved outcomes in a 'real world' outpatient setting. There 
was also preliminary support for its role as a mediator of the effects of positive expectancies 
on outcome, as predicted by Social Cognitive Theory (SCT; Bandura, 1986). High negative 
expectancies had a direct, protective effect on probability of abstinence during treatment, but 
not number of days used or amount used during a lapse. Patients who attended more sessions 
showed greater improvements across all outcomes. Findings provide new insights for health 
professionals administering cognitive-behavioral therapy (CBT). 
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Findings support the critical role of self-efficacy in treatment, as predicted by SCT 
(Bandura, 1986; Connor et al., 2014; Oei and Baldwin, 1994). They are also in line with 
previous reports on the role of self-efficacy in substance use treatment outcome more broadly 
(Adamson et al., 2009; Kadden and Litt, 2011) and specifically in cannabis treatment 
outcome (Litt et al., 2008; Stephens et al., 1995). The current study sought to extend this 
literature by testing the unique contribution of three subtypes of refusal self-efficacy and, of 
those, only emotional relief refusal self-efficacy was related to treatment outcomes. Young et 
al. (2012) previously reported that while all subtypes of refusal self-efficacy were cross-
sectionally related to weekly cannabis consumption, only emotional relief refusal self-
efficacy was associated with severity of dependence. Copeland et al. (2001) reported stress 
relief was the most commonly cited reason for cannabis use in a sample of 229 treatment 
seekers. The current prospective study builds on these findings to show that only emotional 
relief refusal self-efficacy is predictive of cannabis use during CBT treatment where the goal 
is abstinence. According to SCT, with increased specificity self-efficacy becomes more 
predictive of subsequent behavior. Given this, targeting patients’ confidence to refuse 
cannabis use to alleviate negative affect is likely to be more effective than improving self-
efficacy more broadly. Considering the rate of treatment dropout, this may be an important 
early goal in treatment. 
The regulation of negative affect is a primary motivator for breaching abstinence in 
cannabis dependence treatment. Similar results have been reported in the alcohol treatment 
literature (Cooney et al., 1997; Law et al., 2016; Miller et al., 1996). However, the early 
treatment context is important to consider here. Many patients report disposing of available 
cannabis and avoiding cannabis-using peers when commencing treatment, potentially 
reducing the impact of social facilitation and opportunistic refusal self-efficacy beliefs on 
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abstinence. It is possible that these other domains of self-efficacy play a greater role in 
longer-term abstinence and this requires further investigation. Nevertheless, the value in 
distinguishing between refusal self-efficacy subtypes is clear. These results suggest treatment 
should focus on building emotional relief refusal self-efficacy to reduce the likelihood of 
early lapse. This could be achieved through practicing adaptive coping strategies, such as 
cognitive reappraisal or relaxation, as alternative means of regulating affect. Successful 
implementation of these strategies would likely increase emotional relief self-efficacy, reduce 
lapses, and serve to maintain motivation for change (Bandura, 1986). 
High positive cannabis expectancies were associated with lower refusal self-efficacy, 
consistent with the hypothesis that positive expectancies increase substance use by 
undermining self-efficacy (Connor et al., 2014; Gullo et al., 2010). The more rewarding 
cannabis use is believed to be, the more difficult a patient will find it to refuse in cued 
situations. Importantly, expectations of negative reinforcement (tension reduction) are 
included in the positive expectancies scale and are likely to be most relevant to emotional 
relief self-efficacy. These findings support the proposal that self-efficacy acts as the final 
pathway to human behaviour (Bandura, 1999), including cannabis use. Litt et al. (2008) 
reported that increases in refusal self-efficacy was the primary common mechanism through 
which different psychological treatments achieved abstinence at 12 months post-treatment. 
Thus, there are several ways refusal self-efficacy could be strengthened. Our results suggest 
that, for patients reporting strong positive expectancies, challenging these exaggerated beliefs 
about the rewarding effects of cannabis may be an effective method of improving self-
efficacy (Gullo et al., 2010). However, caution is required when inferring directionality here, 
given expectancies and self-efficacy were measured at the same time point. 
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Negative expectancies predicted a lower likelihood of cannabis lapse, consistent with 
Boden et al.’s (2013) analysis of self-initiated abstinence in military veterans. Boden et al. 
also reported negative expectancies predicted average amount consumed, but their study did 
not control for self-efficacy. The present study found no association and this is in line with 
Connor et al.’s (2014) study of court-referred cannabis users not engaged in treatment, who 
also controlled for self-efficacy. Connor et al. reported a positive association between 
negative expectancies and severity of cannabis dependence, but the prognostic implications 
of this were limited by their study’s cross-sectional design. The present results and those of 
Boden et al. demonstrate clearly that negative expectancies predict lower likelihood of lapse. 
The present study further demonstrates that this protective effect is independent of refusal 
self-efficacy and, at least for patients undergoing CBT, is unrelated to the severity of a lapse 
if it occurs. It is likely that pre-treatment negative expectancies are an important determinant 
of motivation for abstinence. Strategies that highlight the negative impact of cannabis on 
patient health will likely further reinforce this motivation (Copersino et al., 2006), 
irrespective of a patient’s confidence in their ability to refuse cannabis. Strategies may 
include cost-benefit analyses and evoking cognitive dissonance over how continued cannabis 
use interferes with long-term goals (Beck et al., 1993; Miller and Rollnick, 2012). The large 
sample and longitudinal design of the present study allows for stronger inferences as to the 
direction of effects between cognition and cannabis use in clinical settings. 
 This study has limitations. Social cognitive variables were only measured together at 
the start of treatment. This limits inferences about direction of effects between expectancies 
and self-efficacy (including mediation), as well as how treatment-related changes in these 
domains affect treatment outcome. Social Cognitive Theory predicts that, in the context of 
substance use, outcome expectancies influence self-efficacy beliefs (Bandura, 2001; Oei and 
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Baldwin, 1994). Tracking session-by-session changes in refusal self-efficacy and 
expectancies could provide valuable insights into which components of CBT more effectively 
impact upon these beliefs and, ultimately, lead to better outcomes (Gwaltney et al., 2005). 
Although pre-treatment assessment is common in addiction research, cannabis withdrawal 
may have impacted on cognition and influenced completion of instruments (Hall, 2015). 
Future research employing independent measures of psychopathology will provide a better 
indication of the role of comorbid mood and anxiety symptoms. This study also relied on 
self-reported cannabis use and abstinence. Future studies could benefit from corroboration 
from biological markers of cannabis metabolites. Lastly, treatment was delivered in a public 
hospital outpatient clinic. While the abstinence program was manualized, fidelity checks 
would have been desirable as treating psychologists were free to diverge from the program in 
accordance with their clinical judgment. On the other hand, this freedom likely increases the 
generalizability of findings to the ‘real world’. 
In conclusion, this is the first study to investigate the unique contribution of outcome 
expectancies and refusal self-efficacy to the prediction of treatment outcome in cannabis 
dependence. Emotional relief self-efficacy was the most consistent predictor of outcome and 
may mediate the effects of positive expectancies on cannabis use, making it an important 
target for psychological treatment. Negative expectancies directly predicted greater likelihood 
of abstinence. Overall, findings provide further support for the utility of Social Cognitive 
Theory in the assessment and treatment of cannabis use disorder. Future studies need to 
employ more frequent assessments of expectancies and self-efficacy to elucidate the dynamic 
association between treatment-related changes in cognition and treatment outcome.  
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Figure Captions 
Figure 1. Mediation of positive cannabis expectancies effect on treatment outcome. 
**p < .01.  
***p < .001. 
Mediation effect on abstinence: CI 95% -0.550, -0.086;  
Mediation effect on days used: CI 95% 0.011, 0.052; 
Mediation effect on amount used: CI 95% 0.012, 0.043. 
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Table 1. Descriptive statistics of the sample (N = 221). 
 
Mean SD Range 
Age (years) 30.10 8.72 18 - 59 
Positive Expectanciesa 51.59 11.84 21 - 86 
Negative Expectanciesa 80.44 19.97 24 - 133 
Emotional Relief Self-Efficacyb 19.58 9.96 6 - 36 
Opportunistic Self-Efficacyb 15.05 7.37 0 - 30 
Social Facilitation Self-Efficacyb 12.94 4.51 0 - 18 
Severity of Dependencec  9.54 2.85 0 - 15 
Anxiety (GHQ-28)d 9.62 5.40 0 - 21 
Depression (GHQ-28)d 6.64 5.93 0 - 21 
Somatic Symptoms (GHQ-28)d 7.34 4.37 0 - 21 
 n %  
Gender    
Male 163 74  
Female 58 26  
Completed High School    
Yes 
107 48.4  
No 114 51.6  
Currently Employed    
Yes 175 79.2  
No 46 20.8  
Note. GHQ-28 = General Health Questionnaire-28 (Goldberg & Williams, 1991).  
aHigher scores reflect higher expectancy. 
bHigher scores reflect greater refusal self-efficacy. 
cHigher scores reflect greater dependence severity. 
dHigher scores reflect poorer psychosocial functioning. 
  
27 
Table 2 
Social cognitive predictors of cannabis abstinence (N = 221). 
Parameter Unstandardized 
coefficient 
SE z p 
Fixed effects     
Constant, β0j 0.318 0.338   
Step 1     
Time between sessionsij -0.009 0.009 1.00 .32 
Session numberij 0.181 0.091 1.99 .047 
Step 2     
Time between sessionsij -0.011 0.009 1.22 .22 
Session numberij 0.177 0.097 1.82 .07 
Positive expectanciesij 0.023 0.015 1.53 .13 
Negative expectanciesij 0.018 0.008 2.25 .024 
Emotional relief self-efficacyij 0.074 0.026 2.85 .004 
Opportunistic self-efficacyij 0.028 0.032 0.88 .39 
Social facilitation self-
efficacyij 
-0.050 0.060 0.83 .41 
Random effects     
Ωu 2.023 0.412   
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Table 3 
Social cognitive predictors of number of days cannabis used (N = 221). 
Parameter Unstandardized 
coefficient 
SE z p 
Fixed effects     
Intercept, β0j 1.699 0.375   
Step 1     
Time between sessionsij 0.014 0.009 1.56 .12 
Session numberij -0.225 0.097 2.32 .02 
Step 2     
Time between sessionsij 0.015 0.010 1.50 .13 
Session numberij -0.226 0.101 2.24 .03 
Positive expectanciesij 0.007 0.020 0.35 .73 
Negative expectanciesij -0.010 0.011 0.91 .36 
Emotional relief self-
efficacyij 
-0.118 0.035 3.37 < .001 
Opportunistic self-efficacyij 0.053 0.042 1.26 .21 
Social facilitation self-
efficacyij 
0.022 0.080 0.28 .78 
Random effects     
σ2e 4.771 0.386   
σ2u0 4.599 0.736   
Deviance (-2*log likelihood) 2240.788    
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Table 4 
Social cognitive predictors of cannabis consumption (in grams, N = 221). 
Parameter Unstandardized 
coefficient 
SE z p 
Fixed effects     
Intercept, β0j 1.019 0.212   
Step 1     
Time between sessionsij 0.005 0.006 0.83 .41 
Session numberij -0.133 0.051 2.61 .01 
Step 2     
Time between sessionsij 0.005 0.006 0.83 .41 
Session numberij -0.132 0.052 2.54 .01 
Positive expectanciesij -0.014 0.015 0.93 .35 
Negative expectanciesij -0.002 0.007 0.29 .77 
Emotional relief self-
efficacyij 
-0.105 0.024 
4.38 
< .001 
Opportunistic self-efficacyij 0.039 0.030 1.30 .19 
Social facilitation self-
efficacyij 
0.075 0.056 
1.34 
.18 
Random effects     
σ2e 0.807 0.080   
σ2u0 1.946 0.297   
Deviance (-2*log likelihood) 1090.330    
 
 
 
